Contents: Eribulin mesilate
Indications: Treatment of patients w/ locally advanced or metastatic breast cancer who have progressed after at least 2 chemotherapeutic regimens for advanced disease. Prior therapy should include an anthracycline & a taxane unless contraindicated.
Contraindications: Hypersensitivity. Lactation.
Adverse Drug Reactions: Neutropenia, leukopenia, anemia, decreased appetite, peripheral neuropathy, headache, nausea, constipation, diarrhea, vomiting, alopecia, arthralgia & myalgia, fatigue/asthenia, pyrexia.
Regulatory Classification: Rx
Manufacturer: Eisai
Distributor: HI-Eisai / Zuellig
